FI973235A0 - Menetelmä IL-6:n vaikutusten inhiboimiseksi - Google Patents

Menetelmä IL-6:n vaikutusten inhiboimiseksi

Info

Publication number
FI973235A0
FI973235A0 FI973235A FI973235A FI973235A0 FI 973235 A0 FI973235 A0 FI 973235A0 FI 973235 A FI973235 A FI 973235A FI 973235 A FI973235 A FI 973235A FI 973235 A0 FI973235 A0 FI 973235A0
Authority
FI
Finland
Prior art keywords
inhibiting effects
inhibiting
effects
Prior art date
Application number
FI973235A
Other languages
English (en)
Swedish (sv)
Other versions
FI973235A (fi
Inventor
Andrew L Glasebrook
Steven H Zuckerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI973235A publication Critical patent/FI973235A/fi
Publication of FI973235A0 publication Critical patent/FI973235A0/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
FI973235A 1995-02-06 1997-08-05 Menetelmä IL-6:n vaikutusten inhiboimiseksi FI973235A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38473095A 1995-02-06 1995-02-06
PCT/US1996/001621 WO1996024356A1 (en) 1995-02-06 1996-02-05 Methods of inhibiting effects of il-6

Publications (2)

Publication Number Publication Date
FI973235A FI973235A (fi) 1997-08-05
FI973235A0 true FI973235A0 (fi) 1997-08-05

Family

ID=23518514

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973235A FI973235A0 (fi) 1995-02-06 1997-08-05 Menetelmä IL-6:n vaikutusten inhiboimiseksi

Country Status (14)

Country Link
EP (1) EP0724879A2 (fi)
JP (1) JPH10513470A (fi)
KR (1) KR19980701933A (fi)
CN (1) CN1173819A (fi)
AU (1) AU708374B2 (fi)
CA (1) CA2212232A1 (fi)
CZ (1) CZ246597A3 (fi)
FI (1) FI973235A0 (fi)
HU (1) HUP9801829A3 (fi)
IL (1) IL117036A0 (fi)
NO (1) NO973609L (fi)
WO (1) WO1996024356A1 (fi)
YU (1) YU6996A (fi)
ZA (1) ZA96897B (fi)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
AU3053199A (en) 1998-04-01 1999-10-25 Ono Pharmaceutical Co. Ltd. Fused thiophene derivatives and drugs containing the same as the active ingredient
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
WO2000039120A2 (en) * 1998-12-30 2000-07-06 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
ES2156550B1 (es) * 1999-04-19 2002-02-01 Univ Navarra Publica Derivados de benzo(b) tiofenosulfonamida-1,1-dioxido y su uso como agentes antineoplasicos.
EP1585507A2 (en) * 2003-01-06 2005-10-19 Wyeth The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW303299B (fi) * 1993-07-22 1997-04-21 Lilly Co Eli
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5521198A (en) * 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5567820A (en) * 1994-05-20 1996-10-22 Eli Lilly And Company Glucopyranoside benzothiophenes

Also Published As

Publication number Publication date
CN1173819A (zh) 1998-02-18
JPH10513470A (ja) 1998-12-22
AU708374B2 (en) 1999-08-05
HUP9801829A2 (hu) 1999-05-28
HUP9801829A3 (en) 1999-10-28
NO973609L (no) 1997-09-11
EP0724879A2 (en) 1996-08-07
AU4916396A (en) 1996-08-27
EP0724879A3 (fi) 1996-09-11
CZ246597A3 (cs) 1998-06-17
WO1996024356A1 (en) 1996-08-15
CA2212232A1 (en) 1996-08-15
IL117036A0 (en) 1996-06-18
YU6996A (sh) 1999-03-04
MX9705940A (es) 1997-10-31
FI973235A (fi) 1997-08-05
ZA96897B (en) 1997-08-05
NO973609D0 (no) 1997-08-05
KR19980701933A (ko) 1998-06-25

Similar Documents

Publication Publication Date Title
NO973009D0 (no) Fremgangsmåte for å inhibere kathepsin-k
NO960059L (no) Fremgangsmåte for behandling av en underjordisk formasjon
FI923421A (fi) Menetelmä siementen päällystämiseksi
NO975159L (no) Fremgangsmåte for kontroll av biologisk nedbrytning
NO971132D0 (no) Fremgangsmåte for inhibering av hydratdannelse
KR19980701899A (ko) 피리티온 함유 코팅 조성물의 변색 방지법
NO971131D0 (no) Fremgangsmåte for inhibering av hydratdannelse
DK0809619T3 (da) Fremgangsmåde til inhibering af hydrat-dannelse
DK0812307T3 (da) Fremgangsmåde til inhibering af hydrat-dannelse
DK0850209T3 (da) Fremgangsmåde til inhibering af hydratdannelse
FI955161A0 (fi) Systeemejä pilokarpiinin säädeltyä vapauttamista varten
FI961378A (fi) Menetelmä N-metyyli-3-(1-metyyli-4-piperidinyyli)-14-indoli-5-etaanisulfonamidin valmistamiseksi
FI973235A0 (fi) Menetelmä IL-6:n vaikutusten inhiboimiseksi
NO975580D0 (no) Fremgangsmåte for å inhibere melanom
FI964266A0 (fi) Polymeerien hajottamismenetelmä
FI103133B1 (fi) Menetelmä glukoosirepression modifioimiseksi
FI980091A0 (fi) Menetelmä ylijäämäaktiivilietteen käsittelemiseksi
NO975699D0 (no) Fremgangsmåte for oksyklorering
IS4285A (is) Aðferð við að hindra útfellingu
NO973103D0 (no) Fremgangsmåte for inhibering av veksthormoneffekter
SE9500112L (sv) Förfarande för ytmodifiering av cement
UA25110A (uk) Спосіб біліосорбції
NO960391L (no) Fremgangsmåte for utvinning av fiskemel
SE9502200D0 (sv) Förfarande för behandling av processavloppsvatten
NO973613D0 (no) Fremgangsmåte for testing av terapautiske forbindelser